Science & Enterprise subscription

Follow us on Twitter

  • The federal health preparedness agency is spending more than $2 billion for developers to produce Covid-19 vaccines… https://t.co/7P1yBG9iO5
    about 13 hours ago
  • New post on Science and Enterprise: BARDA to Buy $2B in Covid-19 Vaccines, Therapies https://t.co/LFM1IUr1rN #Science #Business
    about 13 hours ago
  • A company designing gene-edited T-cells as cancer therapies stopped its clinical trial of a treatment for multiple… https://t.co/0PktfkzyNH
    about 20 hours ago
  • New post on Science and Enterprise: FDA Halts Off-the-Shelf Engineered T-Cell Trial https://t.co/Fbz7IKCgky #Science #Business
    about 20 hours ago
  • If you dig deep into the Science & Enterprise archives, you'll find this site began posting on 6 July 2010, exactly… https://t.co/eGPudMExsK
    about 1 day ago

Please share Science & Enterprise

Early Venture Investors Aim for Diverse Entrepreneurs

Business ideas graphic

A new venture investment company is funding start-ups at their earliest stages, with a goal of increasing support for entrepreneurs from all backgrounds. . . . → Read More: Early Venture Investors Aim for Diverse Entrepreneurs

Amazon Opens $2 Billion Climate Investment Fund

Amazon van at wind farm

Retailing and web services giant Amazon plans to invest $2 billion in sustainable technologies to meet the company’s goal of becoming carbon neutral by 2040. . . . → Read More: Amazon Opens $2 Billion Climate Investment Fund

Gene, Cell Therapy Start-Up Gains $700M in Early Funds

Stem cells

A biotechnology company creating engineered cells with modified genes for treating disease is raising $700 million in its first venture finance round. . . . → Read More: Gene, Cell Therapy Start-Up Gains $700M in Early Funds

Crispr Heart Disease Start-Up Raises New $63M

Heart, circulation system

A one year-old company developing a one-time gene-editing treatment for coronary artery disease is adding $63 million to its first venture funding round. . . . → Read More: Crispr Heart Disease Start-Up Raises New $63M

Start-Up Creating a Simpler, Stable Liquid Biopsy

Blood vials

A new company spun off from University of Oxford is developing a stable and sensitive blood test to detect multiple types of cancer in their early stages. . . . → Read More: Start-Up Creating a Simpler, Stable Liquid Biopsy

Biotechs Apply Crispr Gene-Editing for Hemophilia

Crispr-Cas9 illustration

A treatment for the blood disease hemophilia and other inherited disorders are being developed with the gene-editing technology Crispr in a biotechnology deal. . . . → Read More: Biotechs Apply Crispr Gene-Editing for Hemophilia

Drug Maker Licenses Low-Dose Vaccine Patch

Nanopatch system

The pharmaceutical company Merck is licensing a microneedle patch device that delivers vaccines with a small fraction of the dose normally needed by syringes. . . . → Read More: Drug Maker Licenses Low-Dose Vaccine Patch

Antibody Drug Biotech Raises $105M in Venture Funds

Human B-cell

A company that says it has a faster process for discovering therapeutic antibodies is raising $105 million in its second venture finance round. . . . → Read More: Antibody Drug Biotech Raises $105M in Venture Funds

Merck Inks Three Covid-19 Vaccine, Therapy Deals

SARS-Cov-2 virus

Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections. . . . → Read More: Merck Inks Three Covid-19 Vaccine, Therapy Deals

Psychiatric Drug Maker Raises $80M in Venture Funds

Psilocybe aztecorum

A developer of treatments for mental health disorders based on controlled hallucinogenic substances is raising $80 million in new venture financing. . . . → Read More: Psychiatric Drug Maker Raises $80M in Venture Funds